

## CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 C.F.R. § 1.10

'Express Mail" mailing label number:\_ EV103966515 US Date of Mailing: July 17, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service, utilizing the "Express Mail Post Office to Addressee" service addressed to Assistant Commissioner for Patents, Washington, DC 20231 and mailed on the above Date of Mailing with the above "Express Mail" mailing label number.

(Signature) Helena Beckmann Signature Date: July 17, 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION In re Application Inventor(s): Williams et al. Art Unit: 1633 SC/Serial No.: 09/410,462 Examiner: Sorbello, E. Filed: October 1, 1999 RECEIVED Title: A Single Agent Method for JUL 2 2 2002 Killing Tumor and Tumor TECH CENTER 1600/2900 Associated Endothelial Cells

## RESPONSE TRANSMITTAL LETTER

**Assistant Commissioner for Patents** Washington, DC 20231

**Using Adenoviral Mutants** 

Sir:

Transmitted with this communication in connection with the above-identified application are the following:

A Response under 37 C.F.R. §1.111 to the Office Action dated January 15 [X]09410462

The Commissioner is hereby authorized to charge all fees, including the following [X]fees, associated with this communication, including any extension of time fees that may

be due to Deposit Account No. 15-0615. A duplicate copy of this authorization is enclosed.

- [X] Any filing fees under 37 C.F.R. § 1.16 for the presentation of additional claims.
- [X] Any patent application processing fees under 37 C.F.R. § 1.17 including any applicable fee for extension of time.

Respectfully submitted,

Date: July 17, 2002

Gregory Giptta, Ph.D.

Reg. No.: 32,028

ONYX Pharmaceuticals, Inc. 3031 Research Drive Richmond, California 94806 Telephone (510) 262-8710